Human MCP-4/CCL13(Monocyte Chemotactic Protein 4) ELISA Kit (E-EL-H1159)

This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human MCP-4/CCL13. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human MCP-4/CCL13 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human MCP-4/CCL13, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human MCP-4/CCL13. You can calculate the concentration of Human MCP-4/CCL13 in the samples by comparing the OD of the samples to the standard curve.

CCL13 (MCP-4) was initially identified in a library constructed from human fetal mRNA.CCL13 is constitutively expressed at high levels in the small intestine, colon, and lung. Original data showed that CCL13 was less effective than MCP-1 and MCP-3 in monocyte and lymphocyte chemoattraction, but equivalent to eotaxin as a chemoattractant for eosinophils. Chemokines are very important in the inflammatory process, initially in the influx of PMN by CXC chemokines and subsequently chemoattracting monocytes where the MCPs participate, including CCL13. The bioactivity of pro-inflammatory chemokines is regulated by MMPs in order to regulate the influx of different cell subpopulations. CCL13 is involved in inflammatory diseases such as rheumatoid arthritis (RA), atherosclerosis, and asthma. High levels of CCL13 have been detected in the synovial fluid of patients with RA, in serum of asthmatic patients, and in plasma of patients with symptomatic carotid atherosclerosis.